Provided by Tiger Trade Technology Pte. Ltd.

Biofrontera Inc

1.43
-0.0300-2.05%
Volume:29.56K
Turnover:42.53K
Market Cap:21.24M
PE:-2.64
High:1.47
Open:1.46
Low:1.42
Close:1.46
52wk High:1.55
52wk Low:0.5547
Shares:14.85M
Float Shares:10.55M
Volume Ratio:1.72
T/O Rate:0.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5426
EPS(LYR):-1.0358
ROE:-988.35%
ROA:-17.45%
PB:3.57
PE(LYR):-1.38

Loading ...

Biofrontera Earnings Call: Profits Rise, Risks Remain

TIPRANKS
·
Mar 20

Biofrontera reports Q4 revenue $17.1M vs. $12.6M last year

TIPRANKS
·
Mar 19

Dermatology drugmaker Biofrontera's Q4 revenue rises to record high on Ameluz strength

Reuters
·
Mar 19

BRIEF-Biofrontera Q4 Revenue USD 17.1 Million

Reuters
·
Mar 19

Biofrontera Q4 2025 gross margin jumps 24.4 percentage points to 82.4% on revenue up 36% to USD 17.1 million

Reuters
·
Mar 19

Biofrontera Q4 Operating Expenses USD 12.5 Million

THOMSON REUTERS
·
Mar 19

Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

GlobeNewswire
·
Mar 19

Biofrontera Inc expected to post earnings of 20 cents a share - Earnings Preview

Reuters
·
Mar 17

Biofrontera Sets 2026 Guidance and Highlights Growing U.S. Earn-Out Income

TIPRANKS
·
Mar 11

Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026

GlobeNewswire
·
Mar 10

Biofrontera Reports Positive Phase 2b Acne Trial Results

TIPRANKS
·
Mar 09

Biofrontera Inc - to Present Phase 2B Data to FDA in Q3 2026 for Ameluz Pdt

THOMSON REUTERS
·
Mar 09

Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris

GlobeNewswire
·
Mar 09

Biofrontera Inc - Sun Pharma May Appeal Patent Board Decision

THOMSON REUTERS
·
Feb 26

U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 to Be Unpatentable

THOMSON REUTERS
·
Feb 26

PTAB Invalidates Sun Pharma Patent Claims in Biofrontera Dispute

Reuters
·
Feb 26

Biofrontera Locks Phase 1 PK Study Database for Ameluz in Actinic Keratoses Expansion

Reuters
·
Feb 17

Biofrontera Inc - Supplemental Nda Submission for Extremities, Neck and Trunk Indication Expected in Q3 2026

THOMSON REUTERS
·
Feb 17

Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities

THOMSON REUTERS
·
Feb 17